Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3454 in Patients With Blood Tumors
NCT06218771Phase 2Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB3454 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jul 2023; status: recruiting.
02
Drugs
TQB3454
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06218771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06218771.